Our Aim: Transforming Society through Science

“We will continue research towards fulfilling our dream that most of cancers will be controlled through sophisticated yet widely available immune system interventions by 2050. We therefore envision an integrative, holistic approach to understanding the physiology of health and disease, aided by systems biology approaches and cutting-edge medical technology and bioinformatics.

We bring together basic scientific research with medical disciplines to collaborate in exploring the evolving status of the immune system during cancer development, as well as how it affects other major physiological functions in the nervous, endocrine, circulatory, and gastro-intestinal systems. We aim to create a vibrant scientific environment, empowering researchers to engage with pioneering work in new, integrated fields of medical knowledge.

With the incorporation of cancer immunotherapy into clinical practice, the development of combination therapies, biomarkers, and new cancer immunotherapy-related drugs and devices is being promoted worldwide. However, a large-scale center for cancer immunology was missing in Japan, delaying the development of cancer immunology-related drugs, diagnostics, and devices.

Our center considers collaborative research between academia and pharmaceutical industry necessary for the growth of basic and clinical research, as well as to swiftly deliver results to patients. To actively promote such research and development, CCII’s new research building, completed in FY 2024, is equipped with special spaces for companies. This will facilitate rapid advancement in immunotherapy research in a way that brings together basic, clinical, and corporate researchers, and ensures international competitiveness.”

Prof. Tasuku Honjo
CCII Founding Director